PhoenixBio CoTSE:6190 +2.43%55 Days Payable is 13.58 as of Mar. 2026, which is 36% below its 10-year median of 21.21. GuruFocus rates TSE:6190 with a GF Score™ of 55/100 and a GF Value™ of 円358.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 700 Biotechnology companies, PhoenixBio Co ranks worse than 92.71% on this metric.
The historical rank and industry rank for PhoenixBio Co's Days Payable or its related term are showing as below:
TSE:6190'
s Days Payable Range Over the Past 10 Years
Min: 12.62 Med: 21.21 Max: 28.3
Current: 14.56
During the past 12 years, PhoenixBio Co's highest Days Payable was 28.30. The lowest was 12.62. And the median was 21.21.
TSE:6190's Days Payable is ranked worse than 92.71% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs TSE:6190: 14.56
PhoenixBio Co's Days Payable
declined
from Mar. 2025 (20.09) to Mar. 2026 (13.58).
It may suggest that PhoenixBio Coaccelerated paying its suppliers.
PhoenixBio Co Days Payable Related Terms
PhoenixBio Co Days Payable Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, PhoenixBio Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Days Payable distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PhoenixBio Co's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Days Payable of 13.58 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PhoenixBio Co and its competitors. This is 36% below median its historical median of 21.21. Over the past decade, PhoenixBio Co's Days Payable has ranged from 12.62 to 28.30. According to the industry distribution chart, PhoenixBio Co ranks #649 out of 700 companies in the Biotechnology industry, placing it in the top 92.7%.
Is PhoenixBio Co's Days Payable too high?
PhoenixBio Co's current Days Payable of 13.58 is 36% below median its 10-year median of 21.21. Over the past 10 years, this metric has ranged from a low of 12.62 to a high of 28.30. The Biotechnology industry median Days Payable is 112.83. PhoenixBio Co's value of 13.58 is 88% below this industry median. Based on the distribution chart, PhoenixBio Co ranks #649 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PhoenixBio Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #649 out of 700 companies for Days Payable. This places PhoenixBio Co in the lower half of its industry. The industry median Days Payable is 112.83. PhoenixBio Co's value of 13.58 is 88% below this benchmark. Historically, PhoenixBio Co's own Days Payable has ranged from 12.62 to 28.30 over the past decade. While the company's 10-year median is 21.21 vs. the industry median of 112.83, PhoenixBio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current Days Payable of 13.58 is 88% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PhoenixBio Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current Days Payable is 13.58, which is 36% below median its own 10-year median of 21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円358.63, compared to a current price of 円337.00 — trading 6% below its estimated fair value. The current Days Payable is 13.58, which is 36% below median its 10-year median of 21.21 and 88% below the Biotechnology industry median of 112.83. PhoenixBio Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Days Payable is 13.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円337.00 is trading 6% below its estimated GF Value™ of 円358.63.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Days Payable: 13.58 (36% below median its 10-year median of 21.21)
GF Value™: 円358.63 vs. price of 円337.00 (6% below fair value)
Industry Position: 88% below the Biotechnology median (#649 of 700)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
55GF Score
Get the complete analysis for TSE:6190
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
